CAMP ▲ +5.5% - CAMP4 THERAPEUTICS CORPORATION $CAMP - CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder CAMP4 Therapeutics rose 5.5% today following authorization from UK regulators to begin a Phase 1/2 human clinical trial of its lead candidate CMP-002 in patients with SYNGAP1-related disorder. The regulatory clearance represents a key milestone allowing the company to advance testing of the therapy in human subjects, which typically drives investor optimism in clinical-stage biotech companies. 10-SEP-2026 07:33 AM ET